Receptor status of primary | Number (Percentage) | Allred status of recurrence | Number (Percentage) | Quickscore status of recurrence | Number (Percentage) |
---|---|---|---|---|---|
ER+ | 109 (79.6%) | ER+ | 98 (71.5%) | ER+ | 100 (73.0%) |
 |  | ER- | 11 (8.0%) | ER- | 9 (6.6%) |
ER- | 28 (20.4%) | ER- | 25 (18.2%) | ER- | 24 (17.5%) |
 |  | ER+ | 3 (2.2%) | ER+ | 4 (2.9%) |
PR+ | 85 (62.0%) | PR+ | 63 (46.0%) | PR+ | 53 (38.7%) |
 |  | PR- | 22 (16.0%) | PR- | 32 (23.4%) |
PR- | 52 (38%) | PR- | 40 (29.2%) | PR- | 40 (29.2%) |
 |  | PR+ | 12 (8.8%) | PR+ | 12 (8.8%) |
 |  | HER2 status of recurrence | Number (Percentage) |  |  |
HER2+ | 14 (10.2%) | HER2+ | 13 (9.5%) | Â | Â |
 |  | HER2- | 1 (0.7%) |  |  |
HER2- | 123 (89.8%) | HER2- | 120 (87.6%) | Â | Â |
 |  | HER2+ | 3 (2.2%) |  |  |